U.S. Markets closed

Varian's (VAR) Halcyon to Treat Patients at Japan's Hospital

Zacks Equity Research
Varian's (VAR) Halcyon sees encouraging developments in recent times.

Varian Medical Systems, Inc. VAR recently announced that Ofuna Chuo Hospital, Kamakura City, Kanagawa Prefecture is the first clinic in Japan to begin cancer treatment with the Halcyon radiotherapy system.

 

This secures Varian’s hold in the global radiation therapy space.

 

Halcyon in Focus

 

The Halcyon system has been designed to provide technologically-advanced, high-quality treatment to cancer patients. The platform provides simplified and enhanced image-guided volumetric intensity-modulated radiotherapy. The product claims to be much superior to traditional technologies, thanks to the speed of treatment and improved quality of patient care it offers.

 

The flagship platform has seen a slew of developments in recent times.

 

Notably, Kenya’s The Nairobi West Hospital is the first clinic in the country and in West, Central, and East Africa to begin treating cancer patients using the Halcyonradiotherapy system.

 

Moreover, a 62-year-old male, suffering from thyroid cancer, became the first patient in Malaysia to receive Halcyon treatment at Beacon hospital, Selangor, Malaysia. (Read More: Varian Announces Halcyon's First Successful Case in Malaysia)

 

In the recently reported fiscal second quarter, Varian received the first Halcyon order from China, following its China National Medical Product Administration (NMPA) approval in the recent past. In the quarter, Varian received 36 Halcyon orders as well.

 

Market Prospects

 

MarketsandMarkets projects the global radiotherapy market to reach a worth of $6.8 billion in 2023, at a CAGR of 4.1%. Technological advancements, growing prevalence of cancer and the rising use of particle therapy for cancer treatment drive the market.

 

Other MedTech Giants Operating Globally

 

Other MedTech bigwigs who have fortified their stand globally are Accuray Incorporated ARAY, ABIOMED ABMD and Intuitive Surgical ISRG.

 

Accuray’s Radixact and CyberKnife platforms face robust demand globally. Meanwhile, ABIOMED’s Impella and Intuitive Surgical’s da Vinci platforms rake in huge revenues internationally.

 

Biggest Tech Breakthrough in a Generation

 

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

 

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.

See 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report
 
ABIOMED, Inc. (ABMD) : Free Stock Analysis Report
 
Accuray Incorporated (ARAY) : Free Stock Analysis Report
 
Varian Medical Systems, Inc. (VAR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research